Natera
JP Morgan Healthcare Conference Day 1: Novartis, Gilead, Johnson & Johnson, EQRx, Mirati, and More
Companies provided updates on precision oncology programs for CAR T-cell and biomarker-targeted therapies and announced plans for diagnostic and predictive tests.
BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China
Premium
The molecular residual disease test from Natera was first made available to biopharmaceutical customers and clinicians across China in June.
Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions
Premium
The company believes its findings are the first to show that quantifying ctDNA changes can stratify high-risk colorectal cancer patients into better and worse prognostic groups.
Natera Signatera Test to be Used in Study of MRD-Guided Treatment for Colon Cancer Patients
Patients will be randomized to receive various chemotherapy regimens depending on how Signatera identifies their minimal residual disease status.
Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study
Premium
Investigators analyzed blood samples from patients at two time points after curative-intent surgery, finding that ctDNA MRD status was highly predictive of outcome.